Myron Czuczman, MD

Denileukin diftitox brings a new systemic option for relapsed CTCL, killing tumor cells and Tregs to boost immunity and expand EU access.

Denileukin diftitox transforms CTCL treatment by targeting malignant T cells, offering hope for patients with limited options and severe symptoms.